Showing 1 - 20 results of 28 for search 'F. Ravandi', query time: 0.72s
Refine Results
-
1
P695: PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN CHRONIC PHASE CML by A. Bidikian, H. Kantarjian, E. Jabbour, N. Short, F. Ravandi, G. Issa, K. Sasaki
Published 2022-06-01
Article -
2
P587: COVALENT-101: A PHASE 1 STUDY OF BMF-219, A NOVEL ORAL IRREVERSIBLE MENIN INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, AND M... by F. Ravandi-Kashani, A. Kishtagari, H. Carraway, G. Schiller, E. Curran, B. Yadav, A. Cacovean, S. Morris, T. Butler, J. Lancet
Published 2022-06-01
Article -
3
P499: THE PHASE 1B OMNIVERSE TRIAL OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF RELAPSED/REFRACTORY OR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (TRIAL IN PROGR... by A. H. Wei, H. E. Carraway, L. Taningco, E. Laille, J. Gong, T. Prebet, D. Lopes de Menezes, F. Ravandi
Published 2022-06-01
Article -
4
P497: PROGNOSTIC IMPACT OF RAS AND C-KIT MUTATIONS (SINGLE VS. MULTIPLE) IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA TREATED WITH FLUDARABINE, CYTARABINE, G-CSF (FLAG) BASED REGI... by T. Abuasab, J. Senapati, T. Kadia, F. Ravandi, C. DiNardo, N. Pemmaraju, M. Ohanion, Y. Alvarado, H. Kantarjian, G. Borthakur
Published 2022-06-01
Article -
5
-
6
P703: ASSOCIATION BETWEEN BARIATRIC SURGERY AND OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH ORAL TYROSINE KINASE INHIBITORS by F. Haddad, H. Kantarjian, E. Jabbour, N. Short, A. Bidikian, J. Ning, L. Xiao, N. Pemmaraju, K. Marx, F. Ravandi, K. Sasaki, G. Issa
Published 2022-06-01
Article -
7
PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34) by F. Ong, T. M. Kadia, N. J. Short, M. Yilmaz, Y. Alvarado, S. Pierce, G. Garcia-Manero, C. DiNardo, G. Borthakur, M. Konopleva, N. Daver, H. Kantarjian, F. Ravandi
Published 2022-06-01
Article -
8
P496: CLINICAL CHARACTERISTICS OF SECONDARY MYELOID NEOPLASMS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE by T. Abuasab, S. F. Mohadam, H. Hwang, X. Wang, K. Sasaki, M. Yilmaz, T. Kadia, C. DiNardo, N. Daver, N. Pemmaraju, G. Borthakur, F. Ravandi, G. Garcia-Manero, K. Takahashi
Published 2022-06-01
Article -
9
P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) by T. Kadia, F. Ravandi, G. Borthakur, E. Jabbour, G. Montalban-Bravo, L. Adewale, S. Pierce, C. Lacke, M. Brandt, N. Short, N. Jain, J. Burger, A. Ferrajoli, W. Wierda, H. Kantarjian
Published 2022-06-01
Article -
10
P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEM... by A. Bazinet, T. Kadia, N. Short, G. Borthakur, S. Wang, S. Loghavi, J. Jorgensen, K. Patel, C. DiNardo, N. Daver, Y. Alvarado, F. Haddad, S. Pierce, M. Andreeff, E. Jabbour, M. Konopleva, H. Kantarjian, F. Ravandi
Published 2022-06-01
Article -
11
P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB by W. Macaron, E. Jabbour, M. Konopleva, F. Ravandi, N. Jain, G. Issa, T. Kadia, K. Sasaki, P. Kebriaei, M. Yilmaz, P. Thompson, K. Takahashi, H. Abbas, W. Wierda, R. Garris, H. Kantarjian, N. Short
Published 2022-06-01
Article -
12
P367: LONG TERM OUTCOMES OF NEWLY DIAGNOSED CRLF2 REARRANGED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA by J. Senapati, E. J. Jabbour, N. J. Short, F. Ravandi, P. Kebriaei, T. M. Kadia, G. Borthakur, N. Pemmaraju, R. S. Garris, D. Bansal, S. Konoplev, S. Wang, W. Wang, G. Tang, K. P. Patel, M. Konopleva, N. Jain
Published 2022-06-01
Article -
13
P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES by K. Chien, K. Kim, Z. Li, R. Kanagal Shamanna, F. Ong, G. Montalban Bravo, T. Kadia, E. Jabbour, N. Pemmaraju, D. Hammond, N. Short, F. Ravandi, Y. Alvarado, S. Pierce, X. Q. Dong, H. Kantarjian, G. Garcia-Manero
Published 2022-06-01
Article -
14
P581: PHASE II STUDY OF LOWER-INTENSITY FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH AML WHO ARE UNFIT OR OTHERWISE NOT ELIGIBLE FOR FRONTLINE CLINICAL TRIALS by S. Venugopal, E. Jabbour, N. Pemmaraju, G. Montalban-Bravo, K. S. Chien, N. Daver, N. Jain, J. Burger, Y. Alvarado, A. Maiti, C. D. DiNardo, G. Borthakur, R. Malla, G. Garcia-Manero, F. Ravandi, H. Kantarjian, T. Kadia
Published 2022-06-01
Article -
15
P770: A COMPARATIVE STUDY OF LEUKEMIC TRANSFORMATION IN THERAPY-RELATED AND DE NOVO MYELODYSPLASTIC SYNDROME AFTER HYPOMETHYLATING AGENT FAILURE by K. Kim, F. Ong, Z. Li, R. Kanagal-Shamanna, G. Montalban-Bravo, T. Kadia, E. Jabbour, N. Pemmaraju, D. Hammond, N. Short, F. Ravandi, Y. Alvarado, S. Pierce, X. Q. Dong, H. Kantarjian, G. Garcia-Manero, K. Chien
Published 2022-06-01
Article -
16
P495: PHASE 2 STUDY OF ASTX727 (DECITABINE/CEDAZURIDINE) PLUS VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR PREVIOUSLY UNTREATED, ELDERLY PATIENTS... by T. Abuasab, Y. Alvarado, G. Issa, R. Islam, N. Short, M. Yilmaz, N. jain, L. Masarova, S. Kornblau, E. Jabbour, N. Pemmaraju, G. Montalban-Bravo, S. Pierce, C. DiNardo, T. Kadia, N. Daver, M. Konopleva, G. Garcia-Manero, F. Ravandi
Published 2022-06-01
Article -
17
P365: INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T-ACUTE LYMPHOBLASTIC LEUKEMIA/T-LYMPHOBL... by F. Ravandi, E. Jabbour, N. Jain, T. Kadia, B. Gautam, M. Konopleva, W. Wierda, J. Burger, G. Issa, A. Maiti, H. Balkin, M. Kelly, R. Garris, P. Kebriaei, A. Ferrajoli, G. Garcia-Manero, Y. Alvarado, N. Short, H. Kantarjian
Published 2022-06-01
Article -
18
P541: OUTCOMES AND MANAGEMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PRESENTING WITH HYPERLEUKOCYTOSIS by F. Haddad, K. Sasaki, T. Abuasab, S. Venugopal, D. Rivera Delgado, A. Bazinet, R. Babakhanlou, K. Kim, J. Senapati, F. Ong, S. Desikan, N. Short, N. Pemmaraju, G. Borthakur, C. DiNardo, N. Daver, E. Jabbour, G. Garcia-Manero, F. Ravandi, T. Kadia
Published 2022-06-01
Article -
19
P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG-TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML-001 TRIAL... by A. H. Wei, H. Döhner, H. Sayar, F. Ravandi, P. Montesinos, H. Dombret, D. Selleslag, K. Porkka, J.-H. Jang, B. Skikne, C. Beach, T. Prebet, G. Zhang, A. Risueño, M. Ugidos Guerrero, W. L. See, D. Menezes, G. J. Roboz
Published 2022-06-01
Article -
20
P355: MINI-HYPER-CVD PLUS INOTUZUMAB OZOGAMICIN, WITH OR WITHOUT BLINATUMOMAB, IN OLDER ADULTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATES FROM A PHASE II TRI... by F. Haddad, H. Kantarjian, N. Short, F. Ravandi, N. Jain, W. Macaron, T. Kadia, Y. Alvarado, N. Daver, G. Borthakur, C. DiNardo, M. Konopleva, W. Wierda, J. Jacob, E. Roy, C. Loiselle, A. Milton, J. Rivera, R. Garris, E. Jabbour
Published 2022-06-01
Article